Cardiovascular toxicities following the use of tyrosine kinase inhibitors in Hepatocellular Cancer Patients: A Retrospective, Pharmacovigilance Study

CONCLUSION: Analysis of FAERS data provides a precise profile on the characteristics of cardiac AEs associated with different TKI regimens. Distinct monitoring and appropriate management are needed in the care of TKI recipients.PMID:37608525 | DOI:10.1080/14740338.2023.2251398
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Authors: Source Type: research